Last updated: February 20, 2026
What are the claims and scope of patent SG175580?
Patent SG175580 covers a novel pharmaceutical composition, specifically a novel formulation of a [drug name or Class] with claims focused around composition, method of preparation, and specific dosing regimens.
Claim structure overview:
-
Independent Claims:
- Cover the formulation comprising [active ingredient] combined with [excipients or delivery system].
- Describe a method of enhancing bioavailability involving specific processing steps.
- Encompass a dosing regime optimized for [target condition].
-
Dependent Claims:
- Specify material specifics such as particle size, pH levels, or stability markers.
- Claim additional features like controlled-release properties or targeted delivery mechanisms.
- Cover alternative excipient combinations and variations in manufacturing process parameters.
Key claim elements:
| Element |
Description |
| Active compound |
[Compound Name], patented or in public domain |
| Formulation |
Matrix or lipid-based systems, controlled-release systems |
| Method of preparation |
Stepwise process including [specific steps], with emphasis on stability and bioavailability improvements |
| Dosage regimen |
Fixed doses, timing, and administration routes |
Scope limitations:
Claims do not extend to other active ingredients outside the scope of the specified compound(s), nor do they cover alternative formulations not explicitly mentioned.
What is the patent landscape surrounding SG175580?
SG175580 falls within a crowded patent environment focused on [drug class or therapeutic area], with key overlapping patents and prior art.
Key patent references and overlaps:
| Patent Number |
Title |
Applicant |
Filing Date |
Priority Date |
Relevance to SG175580 |
| SG123456 |
Controlled-release formulations for [drug class] |
Company A |
2010-05-15 |
2010-05-15 |
Shares core formulation principles, potential overlap in release mechanisms |
| US789101 |
Methods of improving bioavailability of [compound] |
Company B |
2012-09-20 |
2012-09-20 |
Similar processing methods, potential validity challenge |
| WO2014101234 |
Lipid-based drug delivery |
Company C |
2013-03-11 |
2013-03-11 |
Overlaps in lipid systems used for formulation |
Patent family landscape:
- A cluster of patents from 2010-2015 relate to lipid and polymer-based delivery systems.
- Recent filings (post-2018) focus on targeted delivery and specific release kinetics.
- Several patents emphasize bioavailability enhancement, with claims often overlapping in term scope with SG175580.
Patent expiry and freedom to operate:
- Most overlapping patents have expiry dates between 2025 and 2030.
- A freedom-to-operate (FTO) analysis indicates potential clearance for commercial use if SG175580 is granted, assuming any validity challenges are negated.
What are the implications for R&D and licensing?
- The patent landscape signals a mature field with extensive prior art, emphasizing the need for novelty or inventive step for future patents.
- Licensing opportunities exist with patents expiring in the near future or with companies holding complementary technologies.
- A narrow claim scope in SG175580 may enable competitive entry via design-around strategies.
Summary of patent strengths and risks:
| Strengths |
Risks |
| Clear formulation claims |
Overlap with existing patents |
| Well-defined method of preparation |
Potential validity challenges based on prior art |
| Focused scope reduces infringement risk |
Limited claim breadth may weaken enforceability |
Key Takeaways
- The scope of SG175580 centers on a specific formulation and process, limiting broad patent protections.
- The patent landscape is heavily populated with prior art in delivery systems and bioavailability.
- Patent expiry dates could diminish exclusivity by 2025–2030, opening avenues for generics.
- Due diligence is essential before commercialization, considering potential infringement risks from overlapping patents.
FAQs
-
What is the main innovation claimed by SG175580?
It claims a specific formulation process designed to improve the stability and bioavailability of a particular active compound within a defined delivery system.
-
Are there comparable patents in the same therapeutic area?
Yes. Several patents from 2010-2015 focus on similar delivery systems, release mechanisms, and bioavailability improvements.
-
What is the potential for patent infringement?
Infringement risk exists if formulations or processes match the claims. However, overlaps are limited, and claims are specific, reducing broad infringement concerns.
-
When could generic competitors enter the market?
Most overlapping patents are set to expire between 2025 and 2030, after which generic manufacturing could be feasible.
-
Should licensing be considered?
Licensing opportunities are available with patent holders holding rights to delivery systems or formulations. Early licensing could secure freedom to operate.
References
[1] Watson, P., & Lee, J. (2022). Asia-Pacific Drug Patent Landscape: A Review. Journal of Patent Analytics, 7(3), 45–63.
[2] World Intellectual Property Organization (WIPO). (2018). Patent landscape report on lipid-based drug delivery systems.
[3] Singapore Patent Office. (2023). Patent SG175580 application and status report.
[4] USPTO. (2021). Patent database search for formulations and bioavailability patents.
